US 12,130,295 B2
NMR system and methods for multi-parameter metabolic vulnerability index evaluations
James D. Otvos, Cary, NC (US); and Irina Y. Shalaurova, Cary, NC (US)
Assigned to LipoScience, Inc., Morrisville, NC (US)
Filed by LipoScience, Inc., Morrisville, NC (US)
Filed on Oct. 22, 2021, as Appl. No. 17/508,309.
Application 17/508,309 is a continuation of application No. 16/124,886, filed on Sep. 7, 2018, granted, now 11,156,621.
Claims priority of provisional application 62/619,497, filed on Jan. 19, 2018.
Claims priority of provisional application 62/555,421, filed on Sep. 7, 2017.
Prior Publication US 2022/0043013 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/92 (2006.01); A61B 5/00 (2006.01); A61B 5/055 (2006.01); G01R 33/465 (2006.01); G16H 10/40 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16Z 99/00 (2019.01); G16B 20/00 (2019.01); G16C 20/20 (2019.01)
CPC G01N 33/92 (2013.01) [A61B 5/055 (2013.01); A61B 5/7275 (2013.01); G01R 33/465 (2013.01); G16H 10/40 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16Z 99/00 (2019.02); G01N 2800/32 (2013.01); G16B 20/00 (2019.02); G16C 20/20 (2019.02)] 19 Claims
 
1. An NMR system comprising:
an NMR spectrometer; and
a processor in communication with the spectrometer configured to obtain (i) at least one NMR signal of a defined GlycA fitting region of NMR spectra associated with GlycA of a blood plasma or serum specimen; (ii) at least one NMR signal of a defined ketone body fitting region of NMR spectra associated with the specimen; (iii) at least one NMR signal of a defined BCAA fitting region of NMR spectra associated with the specimen; and (iv) at least one NMR signal for at least one HDLP subclass; and optionally, at least one NMR signal for serum protein (Protein) and/or citrate (Citrate) fitting region(s) of NMR spectra associated with the specimen.
 
17. A method of monitoring a subject comprising:
obtaining a sample from the subject;
measuring GlycA, at least one high density lipoprotein particle (HDLP) subclass, at least one branched chain amino acid (BCAA), and at least one ketone body (KetoneBody), and optionally, at least one of citrate (Citrate) and/or serum protein (Protein) in the sample;
determining a metabolic vulnerability index (MVX) value based on the measurements; and
evaluating at least whether the MVX value is above a defined level of a population norm associated with increased risk of all-cause mortality.